JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 1997;50:157-160; doi:10.1136/jcp.50.2.157
Copyright © 1997 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Akenami, F O
Right arrow Articles by Vaheri, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Akenami, F O
Right arrow Articles by Vaheri, A
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Neurologic Diseases

Cerebrospinal fluid plasminogen activator inhibitor-1 in patients with neurological disease.

F O Akenami, M Koskiniemi, M Färkkilä, A Vaheri

Haartman Institute, Department of Virology, University of Helsinki, Finland.

AIM: To study cerebrospinal fluid (CSF) concentrations of plasminogen activator inhibitor type-1 (PAI-1) in patients with neurological disease. METHODS: CSF PAI-1 concentrations were measured in 51 patients with neurological disease and 20 reference subjects using an ELISA. The patient group comprised three patients with viral meningitis, 20 with encephalitis, nine with acute lymphoblastic (n = 7) and myeloid (n = 2) leukaemia (with central nervous system involvement), and 19 with multiple sclerosis. RESULTS: Raised PAI-1 concentrations were observed in patients with leukaemia, encephalitis and multiple sclerosis. There was no difference in the mean concentrations of PAI-1 in patients with meningitis when compared with the reference subjects. The highest mean (SEM) PAI-1 concentration was found in patients with leukaemia (1.28 (0.36) ng/ml), and the next highest in those with encephalitis (1.19 (0.20) ng/ml). these values were much higher than those in patients with viral meningitis. In a previous report, raised CSF tissue-type plasminogen activator (tPA) activities were detected in patients with multiple sclerosis, leukaemia and encephalitis, with mean activities in decreasing order. PAI-1 concentrations in the same patients were the reverse of their corresponding tPA activities, being higher in those with leukaemia and encephalitis, than in patients with multiple sclerosis. There was no association between CSF PAI-1 concentrations and age in either patients or controls. Similarly, there was no association between CSF PAI-1 concentrations and urokinase-type plasminogen activator (uPA). CONCLUSIONS: Raised CSF PAI-1 concentrations may be used as a non-specific marker of neurological disease. Moreover, PAI-1 may play an important role in regulating the functions tPA, and probably uPA, in CSF.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
E. East, D. Baker, G. Pryce, H. R. Lijnen, M. L. Cuzner, and D. Gveric
A Role for the Plasminogen Activator System in Inflammation and Neurodegeneration in the Central Nervous System during Experimental Allergic Encephalomyelitis
Am. J. Pathol., August 1, 2005; 167(2): 545 - 554.
[Abstract] [Full Text] [PDF]


Home page
Mol. Interv.Home page
R. A. Adams, M. Passino, B. D. Sachs, T. Nuriel, and K. Akassoglou
Fibrin Mechanisms and Functions in Nervous System Pathology
Mol. Interv., June 1, 2004; 4(3): 163 - 176.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
F. Winkler, S. Kastenbauer, U. Koedel, and H. W. Pfister
Role of the urokinase plasminogen activator system in patients with bacterial meningitis
Neurology, November 12, 2002; 59(9): 1350 - 1355.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
K. Akassoglou, K. W. Kombrinck, J. L. Degen, and S. Strickland
Tissue Plasminogen Activator-mediated Fibrinolysis Protects Against Axonal Degeneration and Demyelination after Sciatic Nerve Injury
J. Cell Biol., May 29, 2000; 149(5): 1157 - 1166.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1997 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.